Gastroenterologia y hepatologia最新文献_第5页

Profiling the patient with inflammatory bowel disease in the relationship between physical activity and partner/social network status: A post hoc patient-tailored analysis of the "BE-FIT-IBD" study. 分析炎症性肠病患者的体育锻炼与伴侣/社交网络状况之间的关系：对 "BE-FIT-IBD "研究**进行的针对患者的事后分析。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-08 DOI: 10.1016/j.gastrohep.2024.502203

Antonietta Gerarda Gravina, Raffaele Pellegrino, Giovanna Palladino, Giuseppe Imperio, Andrea Ventura, Marina Cipullo, Annachiara Coppola, Alessandro Federico

{"title":"Profiling the patient with inflammatory bowel disease in the relationship between physical activity and partner/social network status: A post hoc patient-tailored analysis of the \"BE-FIT-IBD\" study.","authors":"Antonietta Gerarda Gravina, Raffaele Pellegrino, Giovanna Palladino, Giuseppe Imperio, Andrea Ventura, Marina Cipullo, Annachiara Coppola, Alessandro Federico","doi":"10.1016/j.gastrohep.2024.502203","DOIUrl":"10.1016/j.gastrohep.2024.502203","url":null,"abstract":"Introduction: Normal quality of life is an ultimate target in the therapeutic approach to inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC) in the context of which regular physical activity (PA) is often a chimeric parameter that is not standardized in terms of quality/quantity. The study aimed to profile a sample of IBD patients about the relationship between PA-partner status and social network support.Patients and methods: A post hoc analysis of the \"BE-FIT-IBD\" study was set up by stratifying the data of PA with that of partner status and the support that the patient's social network (i.e., relatives, friends) provided in inciting the patient to practice regular PA.Results: In the 219 patients included, there was a greater tendency for patients with stable partners to view the risk of reactivation/worsening of IBD as a barrier to conducting regular PA (p<0.0001). Single patients considered PA more as a protective factor (p=0.045). Patients without a PA-supporting social network retained IBD-related treatment as a PA barrier (p=0.016) and PA as a risk for IBD complications (p=0.01), with less confidence that PA could improve the course of IBD (p<0.001). Rectal syndrome was an IBD-related barrier more represented in patients with PA-deterring social network (p<0.0001).Conclusions: These factors are potential targets for recovering the IBD patient's adherence to regular PA.","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bile acid malabsorption diarrhea as a clinical manifestation of terminal ileum endometriosis. 胆盐吸收不良引起的腹泻是回肠末端子宫内膜异位症的临床表现。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-08 DOI: 10.1016/j.gastrohep.2024.502206

Claudia Herrera-deGuise, Marina Planes-Conangla, Miquel Kraft Carré, Miquel Masachs

引用次数: 0

Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH). a 西班牙肝脏研究协会（AEEH）组织的第五届转化肝脏学会议论文集。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-08 DOI: 10.1016/j.gastrohep.2024.502207

Edilmar Alvarado-Tapias, Douglas Maya-Miles, Agustin Albillos, Rocio Aller, Javier Ampuero, Raul J Andrade, Maria Arechederra, Patricia Aspichueta, Jesus M Banales, Ana Blas-García, Esther Caparros, Teresa Cardoso Delgado, Antonio Carrillo-Vico, Joan Claria, Francisco Javier Cubero, Alberto Díaz-Ruiz, Maite G Fernández-Barrena, Anabel Fernández-Iglesias, Sonia Fernández-Veledo, Ruben Francés, Rocío Gallego-Durán, Jordi Gracia-Sancho, Manuel Irimia, Sabela Lens, María Luz Martínez-Chantar, Beatriz Mínguez, Rocío Muñoz-Hernández, Rubén Nogueiras, Bruno Ramos-Molina, Mar Riveiro-Barciela, Manuel L Rodríguez-Perálvarez, Manuel Romero-Gómez, Guadalupe Sabio, Pau Sancho-Bru, Meritxell Ventura-Cots, Silvia Vidal, Manuel D Gahete

引用次数: 0

Importance of the LARS Score and POLARS Score predictive scale in the ideal treatment of rectal cancer. lars 评分和 polar 评分预测量表在直肠癌理想治疗中的重要性。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-08 DOI: 10.1016/j.gastrohep.2024.502191

Daniel Aparicio López, María Teresa González-Nicolás Trébol, Nieves Sánchez Fuentes, Antonio Martínez Germán, María Victoria Duque Mallén

引用次数: 0

Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease. 评估炎症性肠病患者从静脉注射维多珠单抗到皮下注射维多珠单抗的转变。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-07 DOI: 10.1016/j.gastrohep.2024.502201

Carmen Amor Costa, Cristina Suárez Ferrer, Laura García Ramírez, Eduardo Martín-Arranz, Joaquín Poza Cordón, José Luis Rueda García, María Sánchez Azofra, Irene González Diaz, Clara Amiama Roig, María Dolores Martín-Arranz

{"title":"Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease.","authors":"Carmen Amor Costa, Cristina Suárez Ferrer, Laura García Ramírez, Eduardo Martín-Arranz, Joaquín Poza Cordón, José Luis Rueda García, María Sánchez Azofra, Irene González Diaz, Clara Amiama Roig, María Dolores Martín-Arranz","doi":"10.1016/j.gastrohep.2024.502201","DOIUrl":"10.1016/j.gastrohep.2024.502201","url":null,"abstract":"Aims: The aim of the study is to evaluate the clinical and biochemical response of inflammatory bowel disease patients treated with vedolizumab, 16 weeks after transitioning from intravenous (iv) to subcutaneous (sc).Methods: An observational, prospective, single-center cohort study was performed. Patients with inflammatory bowel disease and maintenance treatment with vedolizumab, stable for at least 4 months, were offered to switch to sc formulation. At the same time of treatment administration a blood test was performed, with vedolizumab levels and fecal calprotectin.Results: Forty-three patients were included, 12 of them (27.9%) chose to transition to sc formulation. All included patients remained in remission during follow-up. At week 16 no significant differences were found in terms of calprotectin levels in patients on iv treatment (mean 146.6±SD 45.9) vs. sc (159.26±53.9) (p=0.9). Vedolizumab serum levels at week 16 were higher in the sc group (22,364.3±5141.6) vs. iv (11,425.9±1514.2) (p=0.009). At week 16, 9 (75%) of the patients in the sc group were highly satisfied with the medication and 11 (91.7%) considered it easy to administer. Four patients (12.9%) in the iv group and 2 (16.6%) in the sc group presented mild adverse effects. The 2 cases (100%) of the sc group the adverse event was local inflammation at the injection site.Conclusion: In our experience, vedolizumab sc is a convenient alternative to iv administration. Vedolizumab serum levels in patients who transitioned to sc were higher than iv formulation.","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease. 炎症性肠病患者对静脉生物治疗对工作和职业环境影响的看法。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-07 DOI: 10.1016/j.gastrohep.2024.502193

Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Margalida Calafat, Federico Bertoletti, Fiorella Cañete, Míriam Mañosa, Alberto López-Faba, Paola Torres, Eugeni Domènech, Esther Garcia-Planella

{"title":"Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease.","authors":"Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Margalida Calafat, Federico Bertoletti, Fiorella Cañete, Míriam Mañosa, Alberto López-Faba, Paola Torres, Eugeni Domènech, Esther Garcia-Planella","doi":"10.1016/j.gastrohep.2024.502193","DOIUrl":"10.1016/j.gastrohep.2024.502193","url":null,"abstract":"Introduction: In the treatment of inflammatory bowel disease (IBD), we have biologic therapies administered intravenously and subcutaneously. Recently, some drugs can be administered by either of these routes. The real impact that intravenous administration has on the perception of the disease and the personal and work life of the patient is unknown.Methods: All IBD patients receiving intravenous infliximab treatment for at least 6 months were anonymously invited to participate. They were provided with a specific structured questionnaire with visual analogue scales (0-10) at two reference centers in the Barcelona area.Results: A total of 90 patients with a median age of 45 years (36-56) and a median infliximab treatment duration of 48 months (24-84) were included. The visit and therapy with infliximab in the day hospital were globally well evaluated (9, IQR 7-10). 78% of patients combined day hospital stays with other activities (26% employment). The personal impact was generally low (4, IQR 0-5.8), but the patient's job was threatened in 43% of patients on intensified treatment.Conclusions: The intravenous administration of biologic drugs on an outpatient basis is highly satisfactory among IBD patients. The impact on the work sphere appears to be more pronounced than on the personal sphere, an aspect that should be considered in shared decision-making with the patient.","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of digital health tools in inflammatory bowel disease. 在炎症性肠病中使用数字健康工具。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-07 DOI: 10.1016/j.gastrohep.2024.502200

Iago Rodríguez-Lago, Beatriz Gros, Kristy Sánchez, Daniel Arumí, M Del Pilar Fortes, Ana Cábez, Francisco Mesonero Gismero

{"title":"Use of digital health tools in inflammatory bowel disease.","authors":"Iago Rodríguez-Lago, Beatriz Gros, Kristy Sánchez, Daniel Arumí, M Del Pilar Fortes, Ana Cábez, Francisco Mesonero Gismero","doi":"10.1016/j.gastrohep.2024.502200","DOIUrl":"10.1016/j.gastrohep.2024.502200","url":null,"abstract":"Objective: To analyse the characteristics and use of digital health tools (DHT) in inflammatory bowel disease (IBD).Methods: We performed a qualitative study based on a narrative literature review, a questionnaire and on the opinion of 3 expert gastroenterologists. Several searches were carried out until September 2022 through Medline to identify articles on the use of DHT in IBD by healthcare professionals. A structured questionnaire was designed to be answered by health professionals involved in the care of patients with IBD. The experts generated a set of recommendations.Results: There are multiple DHT for IBD with different characteristics and contents. We received 29 questionnaires. Almost 50% of the participants were 41-50 years old, the majority were women (83%) and 90% were gastroenterologists. A total of 96% reported the use of several DHT, but 20% used them occasionally or infrequently. Web pages were found the most used (62%). DHT are mostly used to get information (80%), followed by clinical practice issues (70%) and educational purposes (62%). G-Educainflamatoria website is the best known and most used HDS (96% and 64%, respectively). The main barriers to the use of DHT in IBD were the lack of time (55%), doubts about the benefit of DHT (50%) and the excess of information (40%).Conclusions: Healthcare professionals involved in the care of patients with to IBD frequently use DHT, although actions are needed to optimize their use and to guarantee their efficient and safe use.","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protocol for acquisition of images and measurement of transabdominal ultrasound pancreatic two-dimensional shear wave elastography (2D-SWE). 经腹二维剪切波弹性成像（2D-SWE）图像采集和胰腺弹性测量规程。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-07 DOI: 10.1016/j.gastrohep.2024.502198

Eva Marín-Serrano, Ana Barbado Cano, Rubén Fernández Martos, Marta Abadía Barno, Antonio Olveira Martín, Maria Dolores Martín Arranz

{"title":"Protocol for acquisition of images and measurement of transabdominal ultrasound pancreatic two-dimensional shear wave elastography (2D-SWE).","authors":"Eva Marín-Serrano, Ana Barbado Cano, Rubén Fernández Martos, Marta Abadía Barno, Antonio Olveira Martín, Maria Dolores Martín Arranz","doi":"10.1016/j.gastrohep.2024.502198","DOIUrl":"10.1016/j.gastrohep.2024.502198","url":null,"abstract":"Introduction: Transabdominal ultrasound (TU) pancreatic 2D-SWE elastography is a developing technique that needs to be protocolized.Objectives: Establish a protocol for image acquisition and measurement of TU pancreatic - 2D-SWE elastography and estimate the minimum number of measurements to be performed.Materials and methods: Ten measurements of pancreatic elasticity were taken in healthy volunteers using TU-2D-SWE, following a strict protocol for image acquisition and measurement.Results: The 70% of the participants were women, with an average age, weight, and BMI of 49.5±15.7 years, 65.9±11.9kg, and 24.5±4.2kg/m2, respectively. Measurements were taken from the body (70%), tail (16.7%), and pancreatic head (13.3%). The median mean velocity and elasticity were 1.46±0.25cm/sec and 6.46±2.87KPa, respectively. The ROI depth was 4.12±1cm and the SP-ROI distance was 5.2mm on average. There were no statistically significant differences between the 10 measurements. The reliability analysis of the measurements showed high internal consistency and repeatability. Taking 5-6 measurements ensured high concordance with the ten reference measurements. The measurements were significantly lower when the SP-ROI values were intermediate (0.3-0.6cm). The measurement accuracy was higher when performed at a depth less than 4.8cm.Conclusion: To measure pancreatic elasticity using TU-2D-SWE, we propose a strict protocol for image acquisition and measurement, taking a minimum of 5 measurements in the best visualized and accessible pancreatic portion, and preferably at a depth of less than 4.8cm.","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years. 评估过去五年索非布韦/韦帕他韦（SOF/VEL）在西班牙慢性丙型肝炎患者中的临床和经济价值。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-07 DOI: 10.1016/j.gastrohep.2024.502199

Rafael Esteban, Raquel Domínguez-Hernández, Helena Cantero, Miguel Ángel Casado

{"title":"Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years.","authors":"Rafael Esteban, Raquel Domínguez-Hernández, Helena Cantero, Miguel Ángel Casado","doi":"10.1016/j.gastrohep.2024.502199","DOIUrl":"10.1016/j.gastrohep.2024.502199","url":null,"abstract":"Objective: Direct-acting antivirals for the treatment of hepatitis C virus (HCV) represented a paradigm shift. In 2017, sofosbuvir/velpatasvir (SOF/VEL-Epclusa®) was approved, which showed a high cure rate in all patient, contributing to HCV elimination. The analysis aimed to quantify the clinical and economic value of SOF/VEL in HCV chronic patients since its approval in Spain.Methods: An economic evaluation was elaborated adapting a Markov model that simulated the lifetime disease progression in of all HCV chronic patients treated with SOF/VEL (30,488 patients) since its launch (5-years), compared to previous therapies. Patients entered the model and were distributed between the fibrosis states (F0-to-F4) in treated and untreated. All patients (100%) were treated with SOF/VEL regardless of their fibrosis, and 49% with previous therapies in ≥F2. The average sustained viral response (SVR) rates 98.9% SOF/VEL versus 61.0% previous therapies. All parameters for the analysis were obtained from real-life data and literature. Only direct healthcare costs associated with disease management were included. The SOF/VEL value was measured as the number of hepatic complications avoided and their associated cost, and hepatic mortality compared to previous therapies. National Health System perspective and a 3% discount rate was applied.Results: SOF/VEL decreased the number of liver complications, avoiding 92% decompensated cirrhosis, 80% hepatocellular carcinomas, and 87% liver transplants, as well as 85% liver-related mortality. Their cost associated was reduced, amounting to savings of 197M€.Conclusion: SOF/VEL adds relevant value to the HCV treatment, reducing the clinical and economic disease burden and contributing to HCV elimination in Spain.","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccine adherence and adverse events of the SARS-COV vaccine in patients with inflammatory bowel disease. 炎症性肠病患者接种 SARS-COV 疫苗的依从性和不良事件。

IF 1.9 4区医学

Gastroenterologia y hepatologia Pub Date : 2024-05-07 DOI: 10.1016/j.gastrohep.2024.502202

Francisca Isabelle da Silva E Sousa, Raiza Lima Silva, Cezar Nilton Rabelo Lemos Filho, Maria Tereza Oliveira Pereira Santos, Luiz Eduardo Soares Martins, Thais Carvalho de Abreu, Leonardo Freire Alves Nogueira, Sâmya Correia Marques, Marcellus Henrique Loiola Ponte de Souza, Lucia Libanez Bessa Campelo Braga

{"title":"Vaccine adherence and adverse events of the SARS-COV vaccine in patients with inflammatory bowel disease.","authors":"Francisca Isabelle da Silva E Sousa, Raiza Lima Silva, Cezar Nilton Rabelo Lemos Filho, Maria Tereza Oliveira Pereira Santos, Luiz Eduardo Soares Martins, Thais Carvalho de Abreu, Leonardo Freire Alves Nogueira, Sâmya Correia Marques, Marcellus Henrique Loiola Ponte de Souza, Lucia Libanez Bessa Campelo Braga","doi":"10.1016/j.gastrohep.2024.502202","DOIUrl":"10.1016/j.gastrohep.2024.502202","url":null,"abstract":"Objective: To assess adherence to and the adverse effects of the SARS-COV vaccine in patients with inflammatory bowel disease (IBD).Patients and methods: This is an observational, analytical, cross-sectional study. Sociodemographic and clinical data, SARS-COV vaccine data, medications for IBD with use during the vaccination period, and adverse events during the vaccination period were collected. Carried out logistic regressions with robust variance estimation to estimate the odds ratio with the respective 95% confidence intervals (95%CI) to assess the factors associated with non-serious adverse effects following vaccine doses as outcome variables.Results: 194 patients participated, with vaccine compliance of 78.3% for three doses of any vaccine (n=152). Local symptoms and mild systemic symptoms predominated, regardless of the type of vaccine. The first dose of the SARS-COV vaccine with AstraZeneca had a higher percentage of patients with vaccine symptoms. AstraZeneca vaccine increased the chance of non-serious adverse effects in IBD patients by 2.65 times (95% CI: 1.38-5.08; p=0.003), regardless of age, gender, physical activity, excess weight, use of disease-modifying drugs, immunobiological and corticosteroids. CoronaVac vaccine was associated with asymptomatic patients at the first dose and reduced the chance of adverse effects by 0.28 times (OR: 0.284; 95%CI: 0.13-0.62; p=0.002).Conclusion: Local symptoms and mild systemic symptoms predominated, regardless of the type of vaccine. Using CoronaVac in the first dose reduced the chances of adverse effects, while AstraZeneca increased the risk of adverse effects.","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0